<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02122042</url>
  </required_header>
  <id_info>
    <org_study_id>64/14</org_study_id>
    <nct_id>NCT02122042</nct_id>
  </id_info>
  <brief_title>Hyperbaric Oxygen Therapy Can Improve Cognitive Deficits Post Low Grade Glioma Removal Surgery</brief_title>
  <official_title>Hyperbaric Oxygen Therapy Can Improve Cognitive Deficits Post Low Grade Glioma Removal Surgery - Randomized Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to evaluate, in a prospective cross-over, randomized study,
      the effect of hyperbaric oxygen therapy (HBOT) on patients with chronic impairment after low
      grade glioma tumor removal surgery
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive functions</measure>
    <time_frame>6 months</time_frame>
    <description>Cognitive function will be assessed using the one-hour Mindstreams Computerized Cognitive Test Battery at baseline, 3 months and 6 months to intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of live will be evaluated by the EQ-5D,SS-QOL ×• SF36 , QLQ-BN20, questionnaires at baseline , 3 months and 6 months to intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Post Low Grade Glioma Surgery</condition>
  <condition>Cognitive Deficits</condition>
  <arm_group>
    <arm_group_label>HBOT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group will be treated with HBOT for 60 treatments in 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control/Crossover</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Control for 3 months without treatment, and then HBOT for 60 treatments in 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBOT</intervention_name>
    <arm_group_label>HBOT</arm_group_label>
    <arm_group_label>Control/Crossover</arm_group_label>
    <other_name>HBOT of 2 ATA for 90 minutes O2 100%, for 60 treatments</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post low grade glioma (WHO I-II) removal surgery 3-12 months prior to the inclusion in
             the study.

          -  All patients have to have persistent cognitive impairment (Mindstream score should be
             at least one SD lower than average) regarding without noticeable improvement during
             the last month prior to their enrolment.

          -  Age 18 years or older.

        Exclusion Criteria:

          -  Dynamic neurologic/cognitive improvement or worsening during the past month; Previous
             brain radiotherapy and/or radiosurgery. Steroids dependence Chemotherapy in the past
             month or scheduled in the next 3 months Seizures 1 month previous to inclusion Had
             been treated with HBOT for any other reason 1 month prior to inclusion; Have any other
             indication for HBOT; Chest pathology incompatible with pressure changes; Inner ear
             disease; Patients suffering from claustrophobia; Inability to sign written informed
             consent; Smoking patients will not be allowed to smoke during the study and if they
             would not comply with this demand they will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shai Efrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amir Hadanny, MD</last_name>
    <phone>972544707381</phone>
    <email>amir.had@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assaf-Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2014</study_first_submitted>
  <study_first_submitted_qc>April 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2014</study_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assaf-Harofeh Medical Center</investigator_affiliation>
    <investigator_full_name>Assaf Harofeh MC</investigator_full_name>
    <investigator_title>Shai Efrati</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

